ADDITIONAL FILE 1

Implementing genomic screening in diverse populations

Noura S. Abul-Husn^{1,2,3}, Emily R. Soper^{1,2}, Giovanna T. Braganza¹, Jessica E. Rodriguez¹, Natasha Zeid⁴, Sinead Cullina¹, Dean Bobo¹, Arden Moscati^{1,5}, Amanda Merkelson⁵, Ruth J.F. Loos⁵, Judy H. Cho^{2,3,5}, Gillian M. Belbin^{1,2}, Sabrina A. Suckiel^{1,2}, Eimear E. Kenny^{1,2,3}

Corresponding Author:

Noura S. Abul-Husn, M.D., Ph.D. Icahn School of Medicine at Mount Sinai One Gustave L. Levy Place, Box 1003 New York, NY 10029 Telephone: 212-241-3853

Fax: 212-849-2643

Email: noura.abul-husn@mssm.edu

¹The Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY

²Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

³Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY

⁵The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

Supplementary Tables:

- 1. **Table S1.** Questions from a return of genomic results preference survey administered to previously enrolled Bio*Me* Biobank participants.
- 2. **Table S2.** Demographic characteristics of Bio*Me* participants who were respondents of a return of genomic results preference survey (N = 72), and characteristics of all adult Bio*Me* participants enrolled at the time of the survey (N = 31,213).
- 3. **Table S3.** Clinically confirmed pathogenic, likely pathogenic, and downgraded variants in a pilot genomic screening program.

Supplementary Figures:

- 1. **Fig. S1.** A model for returning genomic results to biobank research participants without prior knowledge of genomic risk. After genomics-first identification of variant positive individuals, they receive genetic counseling and are then referred to specialty provider(s) for further evaluation and initiation of risk management.
- Fig. S2. Pre-pilot survey to understand BioMe participants' (N = 72) preferences regarding the hypothetical return of results. A) Decision to enroll into biobank research if the program returned genomic results. B) Selected reasons for receiving or not receiving genomic results.
 C) Selected categories of genomic results participants would want to receive.

Table S1. Questions from a return of genomic results preference survey administered to previously enrolled Bio*Me* Biobank participants.

Question	Answer options		
If, during your enrollment in <i>BioMe</i> ,	Definitely yes		
the recruiter told you that you COULD	Probably yes		
receive genetic research results from	Not sure		
your participation, do you think you	Probably not		
still would have enrolled?	Definitely not		
What do you think are good reasons	To help myself (for example, by finding out what diseases I am at		
to receive genetic research results?	risk for)		
(Check all that apply)	To help my family (for example, by finding out what diseases could run in the family)		
	To help me make decisions about having children (for example, by		
	finding out what diseases could be passed on to them)		
	I feel ownership of my genetic research results		
	Other (please specify)		
What do you think are good reasons	Concerns about my privacy		
NOT to receive genetic research	Concerns about discrimination (health insurance, life insurance,		
results? (Check all that apply)	employment, or other)		
	Cannot make health changes based on genetic research results		
	Receiving genetic research results would cause me or my family		
	anxiety		
	Other (please specify)		
If given the choice, what type of	Only genetic research results that the researcher thinks are		
genetic research results would you	important		
want to receive?	 Only genetic research results about specific diseases that I think are important 		
	Only genetic research results about specific diseases that experts in		
	genetics think are important and should be received by everyone		
	All genetic research results, including those that are uncertain		
	and/or cannot be interpreted at the moment		
	None (I would not want to receive genetic research results)		
If you were to receive genetic	By phone		
research results, how would you want	By a letter in the mail		
to be informed?	In person		
	Not applicable (I would not want to receive genetic research results)		
If you were to receive genetic	My primary care doctor that I see regularly for my healthcare		
research results, who would you want	A genetic counselor (a health professional trained in genetic		
to inform you?	diseases, particularly in returning and discussing implications of		
	genetic testing results)		
	A medical geneticist (a doctor who is specially trained in diagnosing and tracking perpetit diagnose)		
	and treating genetic diseases)		
	A BioMe Biobank researcher or research coordinator Not and include the discount to provide a second coordinator.		
	Not applicable (I would not want to receive genetic research results)		

Table S2. Demographic characteristics of BioMe participants who were respondents of a return of genomic results preference survey (N = 72), and characteristics of all adult BioMe participants enrolled at the time of the survey (N = 31,213).

Demographic characteristics	Survey respondents	BioMe participants	Chi-squared	
(number of survey respondents)	N (%)	N (%) P value		
Female (72)	43 (59.7)	18449 (59.1)	0.9	
Age range (72)				
18 to 30 years	27 (37.5)	2149 (6.9)		
31 to 50 years	16 (22.2)	8823 (28.3)	<0.0001	
51 to 70 years	26 (36.1)	13538 (43.4)		
71 years and over	3 (4.2)	6703 (21.5)	1	
Born in the U.S. (71)	62 (87.3)	19692 (63.1)	<0.0001	
Self-reported ancestry (72)				
African American/African	9 (12.5)	7670 (24.6)		
East/Southeast Asian	2 (2.8)	866 (2.8)	0.07	
Hispanic/Latinx	24 (33.3)	11072 (35.5)		
European	30 (41.7)	9459 (30.3)		
Native American, Other, or Multiple Selected	7 (9.7)	2146 (6.9)		
Jewish (70)	20 (28.6)	-	-	
Identify as religious (69)	39 (56.5)	-	-	
Have children (70)	26 (37.1)	-	-	
Highest level of school completed or highest degree (70)		-	-	
Less than high school degree	1 (1.4)			
High school degree or equivalent (e.g. GED)	4 (5.7)			
Some college but no degree	16 (22.9)			
Associate degree	4 (5.7)			
Bachelor degree	26 (37.1)			
Graduate degree	19 (27.1)			
Average household income (66)		-	-	
Less than \$20,000	9 (13.6)			
\$20,000-\$39,000	6 (9.1)			
\$40,000-\$59,000	14 (21.2)			
\$60,000-\$79,000	9 (13.6)			
\$80,000-\$149,000	10 (15.1)			
\$150,000 or more	18 (27.2)			

Table S3. Clinically confirmed pathogenic, likely pathogenic, and downgraded variants in a pilot genomic screening program.^a

Gene	CHR:POS:REF:ALT	cDNA Position	Protein Position	# Heterozygous Carriers	Interpretation
BRCA1	17:43057062:T:TG	c.5266dupC	p.Gln1756fs	2	Pathogenic
	17:43124027:ACT:A	c.68_69delAG	p.Glu23fs	4	Pathogenic
	17:43094472:C:T	c.1059G>A	p.Trp353Ter	1	Pathogenic
	17:43063917:A:C	c.5109T>G	p.Tyr1703Ter	1	Pathogenic
	17:43049191:TG:T	c.5335delC	p.Gln1779fs	1	Pathogenic
	17:43092615:TC:T	c.2915delG	p.Gly972fs	1	Pathogenic
	17:43091455:T:TGC	c.4074_4075dupGC	p.Gln1359fs	1	Likely pathogenic
	13:32340128:C:T	c.5773C>T	p.Gln1925Ter	1	Pathogenic
	13:32338277:G:T	c.3922G>T	p.Glu1308Ter	2	Pathogenic
	13:32319298:G:T	c.289G>T	p.Glu97Ter	1	Pathogenic
	13:32380085:C:T	c.9196C>T	p.Gln3066Ter	1	Pathogenic
	13:32340300:GT:G	c.5946delT	p.Ser1982fs	3	Pathogenic
	13:32336781:T:G	c.2426T>G	p.Leu809Ter	1	Pathogenic
BRCA2	13:32338783:CA:C	c.4429delA	p.lle1477fs	1	Pathogenic
ı	13:32370955:G:A	c.8488-1G>A		1	Pathogenic
İ	13:32339489:G:T	c.5134G>T	p.Gly1712Ter	1	Pathogenic
	13:32340836:GACAA:G	c.6486_6489delACAA	p.Lys2162fs	1	Pathogenic
ı	13:32336684:G:GA	c.2330dupA	p.Asp777fs	1	Pathogenic
İ	13:32333282:G:T	c.1804G>T	p.Gly602Ter	1	Pathogenic
MLH1	3:37012098:C:T	c.676C>T	p.Arg226Ter	1	Pathogenic
MSH6	2:47799823:TC:T	c.1842delC	p.Cys615fs	1	Pathogenic
	7:6005918:C:A	c.137G>T	p.Ser46lle	1	Pathogenic
PMS2	7:5986838:G:A	c.1927C>T	p.Gln643Ter	1	Pathogenic
	7:5986933:A:AT	c.1831dupA	p.lle611fs	1	Pathogenic
	7:6003793:C:A	c.251-1G>T		1	Likely pathogenic
АРОВ	2:21006288:C:T	c.10580G>A	p.Arg3527Gln	1	Pathogenic
	2:21002392:CAT:C	c.13028_13029delAT	p.Tyr4343fs	2	Uncertain
	2:21006128:G:C	c.10740C>G	p.Asn3580Lys	2	Uncertain
	2:21005155:TG:T	c.11712delC	p.Asn3904Lysfs	1	Pathogenic ^b
	19:11116198:A:G	c.1691A>G	p.Asn564Ser	1	Likely pathogenic
	19:11105441:G:A	c.535G>A	p.Glu179Lys	1	Likely pathogenic
	19:11120143:C:T	c.1897C>T	p.Arg633Cys	1	Pathogenic
İ	19:11123263:C:T	c.2230C>T	p.Arg744Ter	1	Pathogenic
LDLR	19:11105567:G:A	c.661G>A	p.Asp221Asn	1	Pathogenic
	19:11116153:G:A	c.1646G>A	p.Gly549Asp	1	Pathogenic
	19:11113608:G:A	c.1432G>A	p.Gly478Arg	1	Likely pathogenic
	19:11113343:G:A	c.1252G>A	p.Glu418Lys	1	Uncertain
	19:11120106:G:T	c.1860G>T	p.Trp620Cys	1	Uncertain
	19:11120188:T:G	c.1942T>G	p.Ser648Ala	2	Uncertain

	19:11131285:A:G	c.2552A>G	p.Gln851Arg	1	Uncertain
	19:11105507:G:A	c.601G>A	p.Glu201Lys	1	Uncertain
	19:11105572:C:T	c.666C>T	p.D222=	1	Uncertain
TTR	18:31598655:G:A	c.424G>A	p.Val142lle	31	Pathogenic
	18:31592974:G:A	c.148G>A	p.Val50Met	1	Pathogenic

^aOnly Pathogenic and Likely Pathogenic variants associated with conditions included in the pilot genomic screening program were disclosed to consenting participants.

^bThis *APOB* variant is associated with hypobetalipoproteinemia.

cDNA and protein position provided for NM_007294.3 (*BRCA1*), NM_000059.3 (*BRCA2*), NM_000249.3 (*MLH1*), NM_000179.2 (*MSH6*), NM_000535.5 (*PMS2*), NM_000384.2 (*APOB*), NM_000527.4 (*LDLR*), and NM_000371.3 (*TTR*); Human reference genome build 38 (GRCh38).





Figure S1. A model for returning genomic results to biobank research participants without prior knowledge of genomic risk. After genomics-first identification of variant positive individuals, they receive genetic counseling and are then referred to specialty provider(s) for further evaluation and initiation of risk management.



Supplementary Figure 2. Pre-pilot survey to understand BioMe participants' (N = 72) preferences regarding the hypothetical return of results. A) Decision to enroll into biobank research if the program returned genomic results. B) Selected reasons for receiving or not receiving genomic results. C) Selected categories of genomic results participants would want to receive.